Beta Drugs
Ticker > Company >

Beta Drugs share price

Beta Drugs Ltd.

NSE: BETA SECTOR: Pharmaceuticals & Drugs  1.05 L   214   15

1818.45
+0.95 (0.05%)
NSE: 16 Sep 03:31 PM

Price Summary

Today's High

₹ 1842.4

Today's Low

₹ 1817.5

52 Week High

₹ 2215.24

52 Week Low

₹ 1429.52

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyExcellent
The company knows very well the utilization of its assets.
FinancialsVery Stable
The company possesses stable growth history and manageable debt.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

₹ 1835.64 Cr.

Enterprise Value

₹ 1814.13 Cr.

No. of Shares

1.01 Cr.

P/E

118.96

P/B

14.23

Face Value

₹ 10

Div. Yield

0 %

Book Value (TTM)

₹  127.83

CASH

₹ 27.2 Cr.

DEBT

₹ 5.68 Cr.

Promoter Holding

66.73 %

EPS (TTM)

₹  15.29

Sales Growth

25.18%

ROE

20.67 %

ROCE

27.27%

Profit Growth

16.58 %

Add Your Ratio

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.

PE Chart 1w 1m 3m 6m 1Yr 3Yr 5Yr

PB Chart 1w 1m 3m 6m 1Yr 3Yr 5Yr

* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year25.18%
3 Year35.49%
5 Year27.76%

Profit Growth

1 Year16.58%
3 Year46.49%
5 Year23.25%

ROE%

1 Year20.67%
3 Year20.85%
5 Year17.77%

ROCE %

1 Year27.27%
3 Year27.37%
5 Year22.97%

Debt/Equity

0.0489

Price to Cash Flow

86.64

Interest Cover Ratio

29.1514

CFO/PAT (5 Yr. Avg.)

0.982491141880378

Shareholding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Jun 2025 66.73 0.00
Mar 2025 66.73 0.00
Dec 2024 66.73 0.00
Sep 2024 66.73 0.00
Jun 2024 66.73 0.00
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has shown a good revenue growth of 35.4876411760403% for the Past 3 years.
  • Company has been maintaining healthy ROE of 20.8524% over the past 3 years.
  • Company has been maintaining healthy ROCE of 27.3707333333333% over the past 3 years.
  • Company is virtually debt free.
  • Company has a healthy Interest coverage ratio of 29.1514.
  • The company has an efficient Cash Conversion Cycle of 23.8611 days.
  • Company has a healthy liquidity position with current ratio of 2.2393.
  • The company has a high promoter holding of 66.73%.

 Limitations

  • The company is trading at a high PE of 118.96.
  • The company is trading at a high EV/EBITDA of 48.2135.

Quarterly Result (All Figures in Cr.)
 Quarterly Data is not available for this company.Report us

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Net Sales 65.32 79.46 124.85 157.87 197.62
Total Expenditure 53.57 64.15 99.66 126.68 164.1
Operating Profit 11.75 15.31 25.18 31.2 33.53
Other Income 0.42 0.61 0.86 1.04 1.73
Interest 0.64 0.77 0.41 0.84 1.05
Depreciation 2.58 5.27 5.47 6.19 4.72
Exceptional Items 0 0 0 0 0
Profit Before Tax 8.95 9.88 20.16 25.21 29.48
Tax 1.85 2.9 5.92 6.39 7.55
Net Profit 7.1 6.98 14.25 18.82 21.94
Adjusted EPS (Rs.) 7.03 6.91 14.11 18.64 21.73

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Equity and Liabilities
Share Capital 9.61 9.61 9.61 9.61 9.61
Total Reserves 46.83 53.8 67.85 86.64 106.4
Borrowings 3.45 3.39 5.15 3.73 3.62
Other N/C liabilities 0.89 1.45 1.84 1.69 2.36
Current liabilities 22.59 20.34 30.06 35.22 53.26
Total Liabilities 83.37 88.59 114.51 136.89 175.26
Assets
Net Block 31.67 28.01 34.06 34.77 36.48
Capital WIP 0.08 1.9 0 0 0
Intangible WIP 0 0 0 0 0
Investments 6.12 6.54 6.54 6.55 5.77
Loans & Advances 7.18 5.81 6.89 6.78 13.68
Other N/C Assets 0 0.05 0.05 0.05 0.05
Current Assets 38.32 46.28 66.97 88.74 119.27
Total Assets 83.37 88.59 114.51 136.89 175.26
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Profit from operations 8.95 9.88 20.16 25.21 29.48
Adjustment 1.57 4 3.11 0.42 -6.29
Changes in Assets & Liabilities -4.43 -2.28 -4.51 -15.41 -2.01
Tax Paid 0 0 0 0 0
Operating Cash Flow 6.09 11.6 18.76 10.23 21.19
Investing Cash Flow -14.33 -3.15 -12.72 -5.82 -11.02
Financing Cash Flow 9.48 -4.34 1.27 -2.19 -0.76
Net Cash Flow 1.24 4.1 7.31 2.21 9.4

Corporate Actions

Investors Details

PARTICULARS Jun 2024% Sep 2024% Dec 2024% Mar 2025% Jun 2025%
promoters 66.73 66.73 66.73 66.73 66.73
aditi batra 0.01 0.01 0.01 0.01 0.01
heena batra 0.01 0.01 0.01 0.01 0.01
neeraj batra 65.96 65.96 65.96 65.96 65.96
rahul batra 0.41 0.41 0.41 0.41 0.41
varun batra 0.35 0.35 0.35 0.35 0.35
PARTICULARS Jun 2024% Sep 2024% Dec 2024% Mar 2025% Jun 2025%
investors 33.27 33.27 33.27 33.27 33.27
ashish kacholia 5.78 5.78 5.78 5.78 5.78
bsas infotech limited - 1.27 1.27 1.27 1.27
llp 0.02 0.07 0.12 0.15 0.16
onkar singh 1.05 1.05 1.05 1.06 1.06
suryavanshi commotrade pr... - 6.74 6.74 6.74 6.74

Annual Reports

Title Link
Title Link
Annual Report 2020
Annual Report 2018

Ratings & Research Reports

TYPE AGENCY Link
TYPE AGENCY Link
Credit CRISIL
Credit CRISIL
TYPE AGENCY Link
TYPE AGENCY Link
Research Nuvama Wealth
Research Edelweiss
Research NuvamaWealth
Research Nuvama
Research Nuvama Wealth

Concalls & Presentations

TYPE QUARTER Link
TYPE QUARTER Link
Concall Q4FY24
TYPE QUARTER Link
TYPE QUARTER Link
Presentation FY2024

Company News

 No Latest News available for this company.Report us

Beta Drugs Stock Price Analysis and Quick Research Report. Is Beta Drugs an attractive stock to invest in?

Stock investing requires careful analysis of financial data to determine a company's true net worth. This is generally done by examining the company's profit and loss account, balance sheet and cash flow statement, which can be time-consuming and cumbersome.

Examining a company's financial ratios is an easier way to determine its performance, which can help to make sense of the overwhelming amount of information in its financial statements. 

Here are a few indispensable ratios that should be a part of every investor’s research process, or, in simpler words, how to analyse Beta Drugs. 

  • PE ratio: Price to Earnings ratio, which indicates how much an investor is willing to pay for a share for every rupee of earnings. A general rule of thumb is that shares trading at a low P/E are undervalued (it depends on other factors too). Beta Drugs has a PE ratio of 118.95790403297 which is high and comparatively overvalued.

  • Return on Assets (ROA): Return on Assets measures how effectively a company can earn a return on its investment in assets. In other words, ROA shows how efficiently a company can convert the money used to purchase assets into net income or profits. Beta Drugs has ROA of 14.0551% which is a bad sign for future performance. (Higher values are always desirable.)

  • Current ratio: The current ratio measures a company's ability to pay its short-term liabilities with its short-term assets. A higher current ratio is desirable so that the company could be stable to unexpected bumps in business and economy. Beta Drugs has a Current ratio of 2.2393.

  • Return on equity: ROE measures the ability of a firm to generate profits from its shareholders' investments in the company. In other words, the return on equity ratio shows how much profit each rupee of common stockholders’ equity generates. Beta Drugs has a ROE of 20.669%. (Higher is better)

  • Debt to equity ratio: It is a good metric to check out the capital structure along with its performance. Beta Drugs has a Debt to Equity ratio of 0.0489 which means that the company has low proportion of debt in its capital.

  • Sales growth: Beta Drugs has reported revenue growth of 25.1758% which is fair in relation to its growth and performance. 

  • Operating Margin: This will tell you about the operational efficiency of the company. The operating margin of Beta Drugs for the current financial year is 16.9646195970362%.

  • Dividend Yield: It tells us how much dividend we will receive in relation to the price of the stock. The current year dividend for Beta Drugs is Rs 0 and the yield is 0%.

  • Earnings Per Share: It tells us how much profit is allocated to to each outstanding share of a common stock. The latest EPS of Beta Drugs is Rs 15.2865. The higher the EPS, the better it is for investors. 

One can find all the Financial Ratios of Beta Drugs in Ticker for free. Also, one can get the intrinsic value of Beta Drugs by using Valuation Calculators, which are available with a Finology ONE subscription. 

Beta Drugs FAQs

Q1. What is Beta Drugs share price today?
Ans: The current share price of Beta Drugs is Rs 1818.45.

Q2. What is the market capitalisation of Beta Drugs?
Ans: Beta Drugs has a market capitalisation of Rs 1835.643990285 Cr., calculated based on its latest share price.

Q3. What are the P/E and P/B ratios of Beta Drugs?
Ans: The PE ratio of Beta Drugs is 118.95790403297 and the P/B ratio of Beta Drugs is 14.2256563265427, showing how the stock is valued against its earnings and book value.

Q4. What is the 52-week high and low of Beta Drugs share?
Ans: The 52-week high share price of Beta Drugs is Rs 2215.2380952381, and the 52-week low share price of Beta Drugs is Rs 1429.52380952381.

Q5. Does Beta Drugs pay dividends?
Ans: Currently, Beta Drugs does not pay dividends. Dividend yield of Beta Drugs is around 0%.

Q6. What are the face value and book value of Beta Drugs shares?
Ans: The face value of Beta Drugs shares is Rs 10, while the book value per share of Beta Drugs is around Rs 127.8289. Face value is the nominal value set by the company, whereas book value reflects its accounting worth.

Q7. What is the debt of Beta Drugs?
Ans: Beta Drugs has a total debt of Rs 5.6785 Cr., which affects investor sentiment and financial stability. 

Q8. What are the ROE and ROCE of Beta Drugs?
Ans: The ROE of Beta Drugs is 20.669% and ROCE of Beta Drugs is 27.2719%. ROE shows how efficiently the company is generating profit from shareholders’ equity, while the ROCE is reflects how efficiently the company uses its capital to generate returns.

Q9. Is Beta Drugs a good buy for the long term?
Ans: The Beta Drugs long-term outlook depends on debt levels, earnings growth, and sector trends. If it sustains profits and manages debt well, it may be considered for long-term investment.

Q10. Is Beta Drugs undervalued or overvalued?
Ans: Based on valuation ratios like P/E, P/B, and EV/EBITDA, one can analyse whether the Beta Drugs appears undervalued or overvalued at current levels. You can check detailed valuation metrics and peer comparisons on Finology Ticker.

Q11. How to check Beta Drugs’s financials?
Ans: You can review Beta Drugs’s financial statements - including balance sheet, income statement, and quarterly results - on Finology Ticker.

Last Updated on:
Brief about Beta Drugs

Beta Drugs Limited Financials: Check Share Price, Balance Sheet, Annual Report, Quarterly Results, Shareholding, Company Profile and News for Company Analysis

Beta Drugs Limited is a leading pharmaceutical company engaged in the development, manufacturing, and marketing of a wide range of therapeutic products. With a strong presence in the market, Beta Drugs Limited is committed to providing high-quality pharmaceuticals that meet global standards.

Beta Drugs Limited: Share Price

Stay updated with the latest share price information of Beta Drugs Limited on our stock analysis page. Our comprehensive stock analysis tools provide real-time data, allowing investors to make informed decisions based on the latest market trends and developments.

Beta Drugs Limited: Balance Sheet

Access the balance sheet of Beta Drugs Limited and analyze the company's financial position. Our pre-built screening tools help long-term investors assess the company's stability and growth potential. Furthermore, our premium features, such as DCF Analysis, BVPS Analysis, Earnings multiple approach, and DuPont analysis, enable investors to calculate fair value and determine the overall financial health of the company.

Beta Drugs Limited: Annual Report

Obtain the annual report of Beta Drugs Limited from our website. The annual report offers a comprehensive overview of the company's performance, achievements, and future prospects. Long-term investors can gain valuable insights into the company's strategy, financial results, and market outlook through the annual report.

Beta Drugs Limited: Dividend

Explore the dividend history of Beta Drugs Limited and stay updated with the latest payouts. Dividends play a significant role in long-term investing, and our stock analysis page provides information on the company's dividend track record.

Beta Drugs Limited: Quarterly Result

Analyze the quarterly results of Beta Drugs Limited using our stock analysis tools. By studying the company's performance on a quarterly basis, investors can assess its financial trajectory and identify trends. Our premium features, including DCF Analysis, BVPS Analysis, Earnings multiple approach, and DuPont analysis, offer a comprehensive view of the company's profitability and operational efficiency.

Beta Drugs Limited: Stock Price

Get real-time stock price updates for Beta Drugs Limited on our stock analysis page. Our easy-to-use platform enables investors to monitor price movements, track historical data, and analyze trends. Stay informed and make well-informed investment decisions.

Beta Drugs Limited: Price Chart

Visualize the price movements of Beta Drugs Limited through our interactive price charts. Our user-friendly charts provide a graphical representation of the company's stock performance, assisting long-term investors in identifying patterns and potential buying or selling opportunities.

Beta Drugs Limited: News

Stay up-to-date with the latest news and updates related to Beta Drugs Limited. Our stock analysis page curates news articles from reliable sources, ensuring that investors have access to the most relevant and timely information. Our news section helps investors stay informed about market developments, regulatory updates, and any significant events affecting the company.

Beta Drugs Limited: Concall Transcripts

Access the conference call transcripts of Beta Drugs Limited on our website. Transcripts provide insights into management discussions, strategies, and outlooks. By studying these transcripts, investors can gain a deeper understanding of the company's operations and future plans.

Beta Drugs Limited: Investor Presentations

Download investor presentations from Beta Drugs Limited to gain a comprehensive view of the company's growth plans, strategy, and market opportunities. These presentations offer valuable information to long-term investors looking to understand the company's vision and potential.

Beta Drugs Limited: Promoters

Learn about the promoters of Beta Drugs Limited, the key individuals behind the company's success. The promoters play a crucial role in shaping the company's strategy and overall direction. Understanding the background and experience of the promoters helps investors assess the company's leadership.

Beta Drugs Limited: Shareholders

Discover the major shareholders of Beta Drugs Limited. Knowing the key investors and their stake in the company provides insights into the market sentiment and confidence in the company's future prospects.

At Beta Drugs Limited, we understand the importance of providing investors with comprehensive stock analysis tools and resources. Our stock analysis page offers a wide range of information, including company profile, share price, balance sheet, annual reports, dividend history, quarterly results, stock price charts, news updates, concall transcripts, investor presentations, details about promoters, and major shareholders. With our premium features, investors can calculate fair value using tools such as DCF Analysis, BVPS Analysis, Earnings multiple approach, and DuPont analysis. Access all these resources on our website and make informed decisions for long-term investing.

Read More
X